Keros Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | During market hours | – | $-1.45 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | $14.26M | $-0.18 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | During market hours | $3.00M | $-1.14 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $388.00K | $-1.41 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | During market hours | – | – | – |
Press releases
Announcements Keros Therapeutics filed with the SEC
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
Other events · EX-99.1 to Form 8-K
Corporate Presentation Rinvatercept (KER-065) 4
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Appoints Anne Prener to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Other events · EX-99.1 to Form 8-K
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Other events · EX-99.2 to Form 8-K
Corporate Presentation Rinvatercept (KER-065) 4
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation Rinvatercept (KER-065) 4
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics Announces Plan for Return
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Other events · EX-99.1 to Form 8-K
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation KER-065: Neuromuscular Diseases 4
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Keros Therapeutics Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Other events · EX-99.1 to Form 8-K
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Keros Therapeutics Announces Participation at Goldman Sachs 46 th Annual Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Results from the Cibotercept TROPOS PAH Phase 2 Trial May 29, 2025
Exit or restructuring costs · Other events · EX-99.2 to Form 8-K
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics Announces Review of Strategic Alternatives
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
Other events · EX-99.1 to Form 8-K
KER-065 Update KER-065: Phase 1 Clinical Trial Data 7
Other events · EX-99.2 to Form 8-K
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
Other events · EX-99.1 to Form 8-K
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
Other events · EX-99.1 to Form 8-K
Corporate Presentation KER-065: Neuromuscular Diseases 13
Regulation FD disclosure · EX-99.1 to Form 8-K